Follow this page and receive
notifications about new suppliers
Alirocumab API Manufacturers
compare suppliers & get competitive offers
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Follow us
Producer
Produced in:
Established in: 2019
MOQ: 1 g
Employees: 10+
Focused on pharmaceutical industry
Reasonable price for the customers
Full service from R&D stage to commercial stage
+ 0
All certificates
Producer
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Alirocumab API 1245916-14-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Alirocumab. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Alirocumab
- Cas Number:
- 1245916-14-6
- DrugBank number:
- DB09302
- Unique Ingredient Identifier:
- PP0SHH6V16
About Alirocumab
Here is a short description about Alirocumab. Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.
Do you want to buy this product? Send an inquiry to the listed suppliers that meets your quality requirements
Alirocumab is a type of PCSK9-inhibitors
PCSK9 inhibitors belong to the subcategory of pharmaceutical active pharmaceutical ingredients (APIs) and are widely used in the treatment of hypercholesterolemia, specifically for patients with familial hypercholesterolemia or those who are unable to achieve optimal cholesterol levels through traditional therapies.
PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that plays a crucial role in regulating the number of low-density lipoprotein (LDL) receptors on the surface of liver cells. These receptors are responsible for removing LDL cholesterol from the bloodstream. Inhibiting the action of PCSK9 can lead to increased LDL receptor availability, resulting in enhanced LDL cholesterol clearance and lowered LDL cholesterol levels.
Pharmaceutical API subcategory PCSK9 inhibitors are designed to target PCSK9 and prevent it from binding to LDL receptors. This inhibition allows for increased recycling and preservation of LDL receptors on liver cells, leading to improved LDL cholesterol clearance and reduced LDL cholesterol levels in the blood.
PCSK9 inhibitors, such as evolocumab and alirocumab, are typically administered through subcutaneous injections. These drugs have demonstrated significant efficacy in reducing LDL cholesterol levels and have shown great promise in preventing cardiovascular events in high-risk patients.
The development of PCSK9 inhibitors represents a breakthrough in the management of hypercholesterolemia, particularly in patients who do not respond well to statin therapy or who require additional LDL cholesterol reduction. Ongoing research aims to optimize PCSK9 inhibitors' efficacy, safety, and dosing regimens to further enhance their clinical impact on cardiovascular health.
Alirocumab (PCSK9-inhibitors), classified under Lipid-lowering agents
Lipid-lowering agents are a category of pharmaceutical active ingredients (APIs) that are widely used in the treatment of hyperlipidemia, a condition characterized by elevated levels of lipids (such as cholesterol and triglycerides) in the blood. These agents play a crucial role in managing lipid abnormalities and reducing the risk of cardiovascular diseases.
One of the most commonly prescribed lipid-lowering agents is statins. Statins work by inhibiting an enzyme called HMG-CoA reductase, which is responsible for the production of cholesterol in the liver. By blocking this enzyme, statins effectively lower cholesterol levels in the bloodstream.
Another class of lipid-lowering agents is fibric acid derivatives, which primarily target triglyceride levels. These agents activate a nuclear receptor known as PPAR-alpha, which regulates lipid metabolism. By activating PPAR-alpha, fibric acid derivatives enhance the breakdown of triglycerides and increase the elimination of fatty acids from the bloodstream.
Additionally, bile acid sequestrants are often used as lipid-lowering agents. These agents bind to bile acids in the intestine, preventing their reabsorption. As a result, the liver utilizes more cholesterol to produce new bile acids, leading to a decrease in circulating cholesterol levels.
Lipid-lowering agents are available in various formulations, including tablets, capsules, and suspensions, allowing for convenient administration. They are usually prescribed alongside lifestyle modifications, such as dietary changes and regular exercise, to optimize the management of hyperlipidemia.
It is important to note that the use of lipid-lowering agents should be under the supervision of a healthcare professional, as they may have potential side effects and interactions with other medications. Proper monitoring of lipid levels and regular follow-up visits are essential for ensuring the effectiveness and safety of these pharmaceutical agents.
Alirocumab manufacturers | traders | suppliers
We have 2 companies offering Alirocumab produced in 2 different countries.
Get in contact with the supplier of your choice:
- Apino Pharma Co., Ltd. from China, product country of origin China
- Sanofi from France, product country of origin France
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.
